The long-term data suggest that CD19 CAR T-cell therapy can lead to a cure in approximately 30–40% of patients with DLBCL and related aggressive B-NHLs, including those with high-risk features, such as primary refractory disease or relapse within one year of frontline therapy [14]. Here, CD19 is linked to diffuse large B-cell lymphoma.